Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer
| Autor: | Stefan Barth, Dirk Bauerschlag, Fleury Augustin Nsole Biteghe, Eden Padayachee, Zaria Malindi |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
biology medicine.drug_class business.industry medicine.medical_treatment Photoimmunotherapy Review Article Hematology Monoclonal antibody Small molecule Fusion protein Targeted therapy SNAP-tag 03 medical and health sciences 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Immunology medicine Cancer research biology.protein Immunology and Allergy Single-chain variable fragment Antibody business |
| Zdroj: | Transfusion Medicine and Hemotherapy. 44:303-310 |
| ISSN: | 1660-3818 1660-3796 |
| DOI: | 10.1159/000479979 |
| Popis: | Considerable research efforts have been dedicated to understanding ovarian and breast cancer mechanisms, but there has been little progress translating the research into effective clinical applications. Hence, personalized/precision medicine has emerged because of its potential to improve the accuracy of tumor targeting and minimize toxicity to normal tissue. Targeted therapy in both breast and ovarian cancer has focused on antibodies, antibody drug conjugates (ADCs), and very recently the introduction of human antibody fusion proteins. Small molecule inhibitors and monoclonal antibodies (mAbs) are used in conjunction with chemotherapeutic drugs as a form of treatment but problems arise from a board expression of the target antigen in healthy tissues. Also, insufficient tumor penetration due to tight binding affinity and macromolecular size of mAbs compromise the efficacy of these ADCs. A more targeted approach is thus needed, and ADCs were designed to meet this need. However, in ADCs the method of conjugation of drug to antibody is >1, altering the structure of the drug which leads to off-target effects. Random conjugation also causes the drug to affect the pharmokinetics and biodistribution of the antibody and may cause nonspecific binding and internalization. Recombinant therapeutic proteins achieve controlled conjugation reactions and combine cytotoxicity and targeting in one molecule. They can also be engineered to extend half-life, stability and mechanism of action, and offer novel delivery routes. SNAP-tag fusion proteins are an example of a theranostic recombinant protein as they provide a unique antibody format to conjugate a variety of benzyl guanine modified labels, e.g. fluorophores and photosensitizers in a 1:1 stoichiometry. On the one hand, SNAP tag fusions can be used to optically image tumors when conjugated to a fluorophore, and on the other hand the recombinant proteins can induce necrosis/apoptosis in the tumor when conjugated to a photosensitizer upon exposure to a changeable wavelength of light. The dual nature of SNAP-tag fusions as both a diagnostic and therapeutic tool reinforces its significant role in cancer treatment in an era of precision medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|